Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows drug can heal, reduce recurrence of fistulas in Crohn’s disease

26.02.2004


An international study has found that maintenance therapy with the drug infliximab, a monoclonal antibody used to treat Crohn’s disease, can prevent or delay the recurrence of fistulas, a common complication of that inflammatory bowel disorder. As reported in the February 26 New England Journal of Medicine, patients receiving infliximab on a regular basis were twice as likely to avoid fistula recurrence than were patients receiving a placebo.



The study was largely supported by the pharmaceutical firm Centocor, a subsidiary of Johnson & Johnson, which markets infliximab under the brand name Remicade.

Crohn’s disease is a chronic inflammatory disorder of the digestive tract that affects about half a million people in the U.S. Patients with more severe symptoms may develop fistulas – openings from affected areas of the intestine into other organs or onto the skin, often around the anus. The presence of fistulas can seriously impact patients’ quality of life and increases the likelihood of surgical treatment, which may not have satisfactory results. Infliximab, which targets the inflammatory protein tumor necrosis factor, has been shown in previous research to reduce symptoms in patients without this complication and to heal fistulas over a limited period of time.


"Fistulas can be a devastating complication of Crohn’s disease," says Bruce Sands, MD, of the Massachusetts General Hospital (MGH) Gastrointestinal Unit, lead author of the report. "While neither medical nor surgical therapy is perfect in treating this complication, our study has shown that maintenance treatment with infliximab can produce durable closure of fistulas in many patients."

The current study – carried out at 45 sites in North America, Europe and Israel – enrolled adult patients with fistulizing Crohn’s disease not previously treated with infliximab. Almost 300 participants completed a preliminary phase of treatment, receiving three intravenous doses of infliximab over six weeks. They were evaluated several weeks later to determine whether they responded to the infliximab treatment – defined as a 50 percent or greater reduction in the number of draining fistulas – and subsequently randomized into groups receiving either continuing infliximab doses every eight weeks or placebo infusions. Neither participants nor the researchers knew to which groups patients were assigned.

Among participants who initially showed a response to infliximab, fistulas recurred much less frequently among those receiving continuing treatment than in the placebo group. At the end of the 54-week study, almost half those receiving infliximab still showed some response, with more than one-third remaining free of fistulas. Less than 20 percent of the placebo group stayed fistula-free during the same time period.

"The benefits of infliximab in this patient population go beyond closing of fistulas," Sands explains. "These patients also have a reduction in other symptoms and demonstrable improvement in their quality of life. While infliximab is not effective for all patients, the impact can be remarkable for those who do respond." Sands is an assistant professor of Medicine at Harvard Medical School.

The researchers also note that continuing treatment at fixed intervals appears superior to waiting until symptoms recur to reinstate therapy. Patients in the placebo group who redeveloped fistulas during the study could resume infliximab treatment, but although many experienced a renewed response to the medication, they all had to deal with worsening symptoms. Since infliximab does suppress part of the immune response, patients on sustained therapy should be followed closely for evidence of infection or other serious side effects.

Additional authors of the NEJM paper include senior author Sander van Deventer, MD, PhD, of Academisch Medisch Centrum, Amsterdam; Frank Anderson, MD, Vancouver Hospital; Charles Bernstein, MD, University of Manitoba; William Chey, MD, D.Sc., Rochester Institute for Digestive Diseases and Sciences; Brain Feagan, MD, University of Western Ontario; Richard Fedorak, MD, University of Alberta; Michael Kamm, MD, St. Mark’s Hospital, London; Joshua Korzenik, MD, Washington University School of Medicine; Bret Lashner, MD, Cleveland Clinic Foundation; Jane Onken, MD, Duke University; Daniel Rachmilewitz, MD, Tel Aviv Sourasky Medical Center; Paul Rutgeerts, MD, PhD, University Hospital Leuven, Belgium; Gary Wild, MD, PhD, Montreal General Hospital; and Douglas Wolf, MD, Atlanta Gastroenteroloy Associates. Co-authors from Centocor are Paul Masters, Susan Travers, MD, and Marion Blank, PhD.


Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $350 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women’s Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>